Lantern Pharma announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manager, where she will be responsible for oversight of the planned clinical trials, including the planned Phase 2 clinical trial of LP-300 as a combination therapy in never-smokers with Non-Small Cell Lung Cancer (NSCLC). Dr. Kochat brings 30 years of experience with multiple successful drug candidates and management of teams of all phases and sizes in CMC, GxP and GLP, as well as quality regulatory affairs. He has years of hands-on experience authoring, reviewing and approving GMP quality documents, including 3 oncology NDAs, 4 ANDAs, and 13 preclinical programs, as well as oversight of CMOs and CROs. Most recently, Dr. Kochat has served as Director, Pharmaceutical Operations & Business Development at the Plough Center for Sterile Drug Delivery Solutions (UTHSC), Memphis, where his responsibilities have included leading all end-to-end operations related to cGMP manufacturing and quality affairs, including development, site registration and launch of a sterile, cGMP fill-finish facility.